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The molecular basis of frontotemporal dementia
Abstract
Frontotemporal dementia (FTD) is a clinical syndrome with a heterogeneous molecular basis. Familial
FTD has been linked to mutations in several genes, including those encoding the microtubule-associated
protein tau (MAPT), progranulin (GRN), valosin-containing protein (VCP) and charged multivescicular
body protein 2B (CHMP2B). The associated neuropathology is characterised by selective degeneration
of the frontal and temporal lobes (frontotemporal lobar degeneration, FTLD), usually with the presence
of abnormal intracellular protein accumulations. The current classification of FTLD neuropathology is
based on the identity of the predominant protein abnormality, in the belief that this most closely reflects
the underlying pathogenic process. Major subgroups include those characterised by the pathological tau,
TDP-43, intermediate filaments and a group with cellular inclusions composed of an unidentified
ubiquitinated protein. This review will focus on the current understanding of the molecular basis of each
of the major FTLD subtypes. It is anticipated that this knowledge will provide the basis of future
advances in the diagnosis and treatment of FTD.
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Frontotemporal dementia (FTD) is a clinical syndrome with a heterogeneous
molecular basis. Familial FTD has been linked to mutations in several genes,
including those encoding the microtubule-associated protein tau (MAPT),
progranulin (GRN), valosin-containing protein (VCP) and charged
multivescicular body protein 2B (CHMP2B). The associated neuropathology is
characterised by selective degeneration of the frontal and temporal lobes
(frontotemporal lobar degeneration, FTLD), usually with the presence of
abnormal intracellular protein accumulations. The current classification of
FTLD neuropathology is based on the identity of the predominant protein
abnormality, in the belief that this most closely reflects the underlying
pathogenic process. Major subgroups include those characterised by the
pathological tau, TDP-43, intermediate filaments and a group with cellular
inclusions composed of an unidentified ubiquitinated protein. This review will
focus on the current understanding of the molecular basis of each of the major
FTLD subtypes. It is anticipated that this knowledge will provide the basis of
future advances in the diagnosis and treatment of FTD.
The clinical syndrome of frontotemporal
dementia (FTD) is characterised by progressive
changes in behaviour, personality and/or
language, with relative preservation of memory
(Refs 1, 2, 3). Clinical subtypes include the
frontal (behavioural) variant (fvFTD) and two
forms of primary progressive aphasia (PPA):
primary non-fluent aphasia (PNFA) and
semantic dementia (SD) (Refs 1, 2). FTD is often
associated with an extrapyramidal movement
disorder (parkinsonism or corticobasal
syndrome) or with motor neuron disease
(MND) (Refs 4, 5). FTD accounts for 5–15% of
all dementia and is the second commonest
cause in the presenile age group (Refs 6, 7). A
family history of similar disease is present in
25–50% of patients, indicating a significant
genetic influence (Refs 8, 9, 10).
It should be noted that there are currently two
conventions used for the nomenclature of this
clinicopathological syndrome. Here, we use the
one that is more popular in North America, in
1Institute of Neuropathology, University Hospital of Zu¨rich, Switzerland.
2Institute of Pathology, Department of Neuropathology, University of Basel, Switzerland.
3Department of Pathology, University of British Columbia, Vancouver, Canada.
*Corresponding author: Ian R.A. Mackenzie, Department of Pathology, Vancouver General
Hospital, 855 West 12th Avenue, Vancouver, British Columbia, V5Z 1M9, Canada. Tel: +1 604 875
4480; Fax: +1 604 875 5707; E-mail: ian.mackenzie@vch.ca
expert reviews
http://www.expertreviews.org/ in molecular medicine
1
Accession information: doi:10.1017/S1462399409001136; Vol. 11; e23; July 2009
&Cambridge University Press 2009
T
he
m
o
le
cu
la
r
b
as
is
o
ff
ro
nt
o
te
m
p
o
ra
ld
em
en
ti
a
which FTD is used as the general term for the
clinical syndrome (including all behavioural
and language variants) and the term
frontotemporal lobar degeneration (FTLD) is
reserved for the associated pathology. However,
in the UK, FTLD is often used as the general
term for both the clinical and the pathological
entities, whereas FTD refers only to the clinical
subtype in which behavioural abnormalities
predominate. We recognise that this situation is
confusing; however, both terminologies are
currently in wide use and there is no consensus
as to which is more appropriate.
The molecular genetic basis of FTD is
heterogeneous. Autosomal dominant FTD may
be caused by mutations in several genes,
including those encoding the microtubule-
associated protein tau (MAPT) (Refs 11, 12, 13),
progranulin (GRN) (Refs 14, 15), valosin-
containing protein (VCP) (Ref. 16) and charged
multivescicular body protein 2B (CHMP2B)
(Ref. 17), and several families with FTD and
MND have shown genetic linkage to a locus on
chromosome 9p (Refs 18, 19, 20).
Theneuropathologyassociatedwith clinical FTD
is also heterogeneous (Ref. 21). Relatively selective
degeneration of the frontal and temporal lobes
(frontotemporal lobar degeneration, FTLD) is a
consistent feature, which correlates with the
main clinical manifestations. As with many other
neurodegenerative conditions, the pathology of
most cases of FTD includes the presence of
abnormal intracellular protein accumulations.
Traditionally, these inclusion bodies were
demonstrated with special histochemical staining
techniques, such as silver impregnation methods.
Eponymous and syndromic names were used for
clinical syndromes associated with a specific
morphology and anatomical distribution of
cellular inclusions. However, in many cases,
these clinicopathological correlations turned out
to be imperfect. Modern laboratory techniques,
such as immunohistochemistry, have allowed the
biochemical composition of the pathological
changes to be more readily determined. In recent
years, it has become popular to classify FTLD
pathology based on the presumed molecular
defect, in the belief that this most closely reflects
the underlying pathogenic process (Ref. 21).
In this review, we will use the molecular-based
system of nosology and nomenclature
recommended in a recent consensus paper
(Ref. 22). The term FTLD will be used as the
general terminology for pathological conditions
that are commonly associated with clinical FTD,
and major subdivisions will be designated
by the protein abnormality that is presumed to
be pathogenic or most characteristic (Table 1).
Cases are further subclassified, using traditional
terminology, to define specific patterns of
pathology [i.e. FTLD-tau (PiD) for Pick disease].
Existing descriptive terms are retained for
rare causes of FTD that have characteristic
pathological features of unknown biochemistry
(such as basophilic inclusion body disease,
BIBD). Finally, cases with no inclusions visible
with special histochemical stains or
immunohistochemistry (formerly known as
dementia lacking distinctive histopathology,
DLDH), will be designated FTLD-ni (no
inclusions).
FTLD-tau
Tau protein
Tau is a microtubule-associated phosphoprotein
(MAP) that is abundantly expressed in both the
central and peripheral nervous system. By
promoting microtubule (MT) assembly and
stability, tau plays a fundamental role in
maintaining neuronal integrity and axoplasmic
transport (Refs 23, 24). The tau gene (MAPT) is
located on chromosome 17q21 and has two
major haplotypes, H1 and H2, which are
defined by a set of single nucleotide
polymorphisms and a 238 base pair deletion in
intron 9 (Ref. 25). The H2 haplotype is also
associated with an inversion of a 900 kb
region that includes MAPT (Ref. 26). MAPT
contains 16 exons, 11 of which encode the major
tau protein isoforms (Ref. 27). Through
alternative mRNA splicing of exons 2, 3 and 10,
a set of six isoforms, ranging from 352 to 441
amino acids, are generated in the adult human
brain. Exons 9 to 12 encode four microtubule-
binding motifs, which are imperfect repeats of
31 or 32 amino acids, in the C-terminal half of
the tau molecule. It is these binding domains
that mediate the interaction between tau and
MTs. Alternative splicing of exon 10 generates
tau isoforms with either three (exon 10 missing)
or four (exon 10 present) repeat domains,
known as 3R and 4R tau, respectively (Fig. 1a)
(Refs 28, 29). In Alzheimer disease (AD),
abnormally hyperphosphorylated tau is the
major component of the neurofibrillary lesions
(known as neurofibrillary tangles, neuropil
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threads and dystrophic neurites), whereas b-
amyloid peptide is the major component of
senile plaques. Abnormal intracellular
accumulation of tau is also characteristic of a
number of other neurodegenerative disorders,
collectively known as ‘tauopathies’ (Refs 30,
31). Comparison of the tau aggregates in these
disorders reveals differences in both
phosphorylation and the content of different
tau isoforms. Thus, tauopathies might be
subdivided into disorders with inclusions made
predominantly of 3R or 4R tau or an admixture
of both (Ref. 32). A number of these tauopathies
may be associated with clinical FTD (FTLD-
tau), including Pick disease (PiD), progressive
supranuclear palsy (PSP), corticobasal
degeneration (CBD), argyrophilic grain disease
(AGD) and hereditary frontotemporal dementia
and parkinsonism linked to chromosome 17, as
a result ofMAPTmutations (FTDP-17T) (Ref. 21).
FTLD-tau (PiD)
PiD is the clinicopathological prototype of FTD
(Refs 33, 34, 35). The most distinctive gross
pathological feature is marked atrophy of
the frontal and anterior temporal lobes, also
known as ‘knife-edge’ lobar atrophy (Fig. 2a).
The main histological features consist of severe
neuronal loss, ballooned neurons (Pick cells)
and pathognomonic spherical argyrophilic
neuronal inclusions, called Pick bodies
(PBs) (Fig. 2b). PBs are found mainly in
Table 1. Recommended nomenclature for frontotemporal lobar degenerations
Previous terminology Recommended
terminology
(Ref. 13)
Major
pathological
subtypesa
Associated
gene
Tau-positive FTLD FTLD-tau PiD
CBD
PSP
AgD
MSTD
FTDP-17Tb MAPT
Tau-negative FTLD FTLD-U, TDP-43-
positive
FTLD-TDP Type 1c
Type 2c Chrom. 9p
Type 3c GRN
Type 4c VCP
FTLD-U, TDP-43-
negative
FTLD-UPS aFTLD-U
FTD-3 CHMP2B
NIFID FTLD-IF
DLDH FTLD-ni
Other (BIBD) BIBD
aCharacteristic pattern of pathology, not the clinical syndrome.
bFTDP-17T is not really apathological subtypebecause thepathology varies betweencaseswith differentMAPT
mutations.
cBased on classification system by Cairns et al. (Ref. 100).
Abbreviations: aFTLD-U, atypical frontotemporal lobar degeneration with ubiquitinated inclusions; AgD,
argyrophilic grain disease; BIBD, basophilic inclusion body disease;CBD, corticobasal degeneration;CHMP2B,
chargedmultivescicular body protein 2B gene; chrom. 9p, linked to locus on chromosome 9p; DLDH, dementia
lacking distinctive histopathology; FTD-3, frontotemporal dementia linked to chromosome 3; FTLD,
frontotemporal lobar degeneration; FTLD-U, FTLD with ubiquitinated inclusions; FTDP-17T, frontotemporal
dementia and parkinsonism caused by mutations in the tau gene; GRN, progranulin gene; IF, intermediate
filament;MAPT, microtubule-associated protein tau gene; MSTD, multiple system tauopathy with dementia; ni,
no inclusions; NIFID, neuronal intermediate filament inclusion disease; NII, neuronal intranuclear inclusion; PiD,
Pick disease; PSP, progressive supranuclear palsy; UPS, ubiquitin proteasome system; VCP, gene encoding
valosin-containing protein.
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neocortical neurons of layers II–IV, the granule
cells of the dentate gyrus, pyramidal cells of
the hippocampus, subiculum and entorhinal
cortex, and subcortical nerve cell populations.
PBs are composed predominantly of 3R tau
isoforms (Ref. 32), whereas 4R tau deposits
might be present in glia in a subset of cases
(Refs 36, 37).
FTLD-tau (PSP)
Also known as Steele-Richardson-Olszewski
syndrome (Ref. 38), PSP is the second most-
common parkinsonian disorder, after classical
Parkinson disease. Clinical features typically
include early postural instability, axial dystonia,
supranuclear vertical gaze palsy, pseudobulbar
palsy and parkinsonism that is resistant to
levodopa therapy. Although cognitive
dysfunction is often mild, some cases of PSP
present with dementia and only mild motor
features (Ref. 39). The pathology of PSP is
characterised by gross atrophy of the midbrain
(especially the pretectal region), superior
cerebellar peduncles, subthalamic nucleus and
substantia nigra. Fibrillar tau pathology occurs
in both neurons and glia. Glial inclusions
include tufted astrocytes (Fig. 2c), which are
fairly specific for PSP, as well as thorn-shaped
astrocytes, coiled bodies in oligodendrocytes
and neuropil threads, all of which are also
Tau isoforms and tau gene mutations
Expert Reviews in Molecular Medicine © 2009 Cambridge University Press
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Figure 1. Tau isoforms and tau gene mutations. (a) Six isoforms of the tau protein found in the adult
human brain result from alternative splicing of exons 2 (red), 3 (green) and 10 (yellow). Exons 9–12 encode
imperfectly repeated microtubule-binding repeats (shown in black). (b) Mutations in the tau gene in
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17T). Thirty-six coding region
mutations in exons (E) 1 and 9–13 and eight intronic mutations flanking exon 10 are shown.
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found in other tauopathies. Neurofibrillary
tangles typically have a round or globose
appearance (Fig. 2d). Many subcortical regions
are affected, including the striatum, pallidum,
subthalamic nucleus, substantia nigra,
oculomotor complex, periaqueductal grey,
superior colliculi, basis pontis and dentate
nucleus. Cases of PSP with dementia are also
found to have significant tau pathology in the
cerebral cortex (Ref. 40). Biochemically, the
inclusions in PSP consist predominantly of 4R
tau isoforms (Ref. 41). Inheritance of the H1 tau
gene haplotype predisposes to the sporadic 4R
tauopathies, PSP and CBD (Refs 42, 43).
FTLD-tau (CBD)
CBD is an increasingly recognised
neurodegenerative disease with both motor and
Pathological features in FTLD-tau
Expert Reviews in Molecular Medicine © 2009 Cambridge University Press
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Figure 2. Pathological features in FTLD-tau. (a) Severe atrophy of the frontal and temporal lobes and (b) Pick
bodies in the temporal cortex of a patientwithPickdisease. (c) Tufted astrocyte and (d) a globose tangle in acase
with progressive supranuclear palsy. (e) Astrocytic plaque as a hallmark lesion of corticobasal degeneration. (f)
Abundant argyrophilic grains in the hippocampus of a patient with argyrophilic grain disease. (g) Neurofibrillary
tanglesandneuropil threads in the frontalcortexofacasewith frontal variantAlzheimerdisease.Arrowindicatesa
neuritic plaque. (h) Tau pathology in sector CA2 of the hippocampus in hippocampal sclerosis dementia. (i)
Neuronal and glial tau pathology in the frontal cortex of a patient with an intron 10 þ3 splice-site mutation in
the tau gene. b, d, e, f, h, tau immunohistochemistry; c, g, i, Gallyas-Braak silver stain. Scale bars: 50 mm.
expert reviews
http://www.expertreviews.org/ in molecular medicine
5
Accession information: doi:10.1017/S1462399409001136; Vol. 11; e23; July 2009
&Cambridge University Press 2009
T
he
m
o
le
cu
la
r
b
as
is
o
ff
ro
nt
o
te
m
p
o
ra
ld
em
en
ti
a
cognitive dysfunction (Ref. 44). The initial motor
symptoms are akinesia, rigidity and apraxia.
There is often parkinsonism, which is resistant
to dopaminergic drugs. Recent studies have
found that FTD is also a common clinical
presentation of CBD (Refs 39, 45). Gross
examination typically shows depigmentation of
the substantia nigra and frontoparietal atrophy
that is most severe in the pre- and post-central
areas and often asymmetrical. Swollen,
achromatic neurons were initially thought to be
the most characteristic histological change
(Ref. 44); however, it is now recognised that the
affected cortex and subcortical regions have
abundant glial and neuronal intracytoplasmic
tau pathology. In addition to various neuronal
inclusions, abundant thread pathology, coiled
bodies and thorn-shaped astrocytes, a
particularly characteristic feature of CBD is the
presence of circular rings of short tau-positive
cell processes, referred to as ‘astrocytic plaques’
(Fig. 2e) (Ref. 46). The biochemical profile of the
pathological tau in CBD is similar to that in
PSP, and consists predominantly of 4R tau
isoforms (Refs 30, 31).
FTLD-tau (AGD)
AGD is a sporadic late-onset dementia that
accounts for approximately 5% of all cases of
dementia (Refs 47, 48). The clinical features are
still poorly understood, and it can be difficult
to distinguish from AD (Refs 49, 50). However,
a subset of AGD patients present with clinical
features of FTD (Refs 51, 52). The hallmark
lesions are abundant argyrophilic grains (AGs)
in neuronal processes (Fig. 2f) and coiled
bodies in oligodendrocytes. AGs are abundant
in various limbic structures, including the CA1
sector of the hippocampus, layers II and III of
the entorhinal and transentorhinal cortices, the
amygdala and the hypothalamic lateral tuberal
nuclei (Ref. 47). Recent biochemical studies
have revealed that AGD is also a 4R tauopathy
(Refs 53, 54, 55). At present, there is controversy
over whether the H1 tau haplotype is also a
risk factor for AGD (Ref. 47).
Other sporadic tauopathies
Some additional rare forms or variants of
tauopathies may be associated with clinical
FTD and/or demonstrate a frontotemporal lobar
distribution of tau pathology. These include the
frontal variant of AD (fvAD) (Fig. 2g) (Refs 56,
57), neurofibrillary tangle dementia (reviewed
in Ref. 58), sporadic multiple system tauopathy
with dementia (MSTD) (Ref. 59), and white
matter tauopathy with globular inclusions
(Ref. 60). Although insoluble tau in fvAD and
neurofibrillary tangle dementia contains both
3R and 4R tau isoforms, sporadic MSTD and
white matter tauopathy with globular glial
inclusions are 4R tauopathies. Hippocampal
sclerosis (HS) is a descriptive term for near-
complete, selective loss of pyramidal neurons
in the CA1 sector of the hippocampus and
subiculum. HS can be the primary pathology
in some cases of late-onset dementia (Ref. 61),
but it more frequently occurs in association
with tauopathies (Fig. 2h) (Ref. 62) or FTLD-
TDP (see below) (reviewed in Ref. 63).
FTDP-17T
In 1994, a familial form of FTD and parkinsonism
was linked to chromosome 17q21-22 (Ref. 64).
Over the following years, other families with
autosomal dominant FTD were identified with
linkage to the same region and, based on
similarities in the clinical, neuropathological,
and genetic findings, these were grouped under
the umbrella of FTD and parkinsonism linked
to chromosome 17 (FTDP-17) (Ref. 65). About
half of the original FTDP-17 families were
found to have MAPT mutations (FTDP-17T)
(Refs 11, 12, 13), whereas the genetic cause in
the others remained unknown until recently
(see section on FTLD-TDP). At present, 44
MAPT mutations have been described in 131
families (Fig. 1b) (AD&FTD Mutation database:
http://www.molgen.ua.ac.be/FTDMutations).
Clinically, FTDP-17T is typically characterised
by personality changes, motor symptoms
and cognitive decline. The earliest symptoms
are usually disinhibition, loss of initiative,
obsessive-compulsive behaviour, and/or
psychosis, followed by cognitive decline
leading to profound dementia (Ref. 66).
However, some MAPT mutations result in a
clinical phenotype that more closely resembles
PiD, CBD, PSP, AGD or AD. In all cases of
FTDP-17T, the neuropathology includes various
types of fibrillar tau pathology. Some mutations
are associated with inclusions in both neurons
and glia (Fig. 2i), whereas others lead to a
predominance of neuronal tau pathology.
Depending on the mutation site, tau aggregates
can be composed predominantly of 3R or 4R
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tau isoforms, or a mixture of both. MAPT
mutations are located in the coding region or in
the intron flanking the alternatively spliced
exon 10 (Fig. 1b) and fall into two main
functional categories: those that affect the
alternative splicing of tau pre-mRNA, and those
whose primary effect is at the protein level. The
mechanisms by which the various MAPT
mutations impair tau functions and generate
filamentous tau inclusions are beyond the scope
of this review, but they have recently been
reviewed elsewhere (Refs 28, 66, 67).
FTLD-tau due to other gene abnormalities
In addition to FTDP-17T, there remain many
familial FTLD-tau cases for which no MAPT
mutation has been discovered. Recently, an
interesting association has been described
between familial FTLD-tau and presenilin 1
(PS-1). Mutations in the genes encoding PS-1
and PS-2 (PSEN1 and PSEN2) account for the
majority of early-onset familial AD (Ref. 68).
However, PSEN1 mutations have also been
identified in patients with an FTD presentation
(Ref. 69). In one patient with familial FTD caused
by the G183V PSEN1 mutation, the
neuropathology was found to be consistent with
PiD in the absence of b-amyloid deposits
(Ref. 70), whereas another FTD family with
the M146L mutation had both PBs and AD
pathology (Ref. 71). However, some FTD patients
with PSEN1 mutations have turned out to have
typical AD pathology (Refs 72, 73). Finally, a
family with FTD that was originally attributed to
the PS-1 insR352 change was recently shown to
have a GRN mutation and characteristic FTLD-
TDP pathology (Refs 74, 75). Currently, the
mechanisms by which PSEN1 mutations
contribute to neurodegeneration in a subset of
FTD subjects are still elusive (Refs 76, 77).
FTLD-TDP
Until recently, most cases of tau-negative FTLD
were thought to have no cellular inclusions and
were classified as DLDH (Ref. 78). However, in
the early 1990s, a novel pattern of pathology
was first identified in patients with MND and
dementia (MND-dementia), characterised by
neuronal cytoplasmic inclusions (NCIs) and
dystrophic neurites (DNs), in the superficial
layers of frontotemporal neocortex and dentate
granule cells of the hippocampus, that are
immunoreactive for ubiquitin (ub-ir) but
negative for tau and a-synuclein (Refs 79, 80).
Subsequently, similar ub-ir pathology was
identified in a subgroup of patients with
clinically pure FTD without motor symptoms
(FTD-MND type or MND inclusion dementia)
(Ref. 81). The pathology in cases of MND-
dementia and FTD-MND type was found to be
similar, regardless of the clinical phenotype
(Ref. 82), and became known as FTLD with
ubiquitinated inclusions (FTLD-U) (Ref. 83).
With growing knowledge of this entity amongst
neuropathologists and improvements in
immunohistochemical techniques, FTLD-U
became appreciated as the most common
neuropathological subtype of FTLD (Refs 84,
85). The recognition of distinct patterns of
FTLD-U pathology, raised the possibility
that this might actually be a heterogeneous
group of disorders, each with a different
ubiquitinated protein (Refs 86, 87). However,
this issue was largely resolved in 2006, when
the transactive response (TAR) DNA-binding
protein with a mass of 43 kDa (TDP-43) was
identified as the pathological protein in the vast
majority of clinical and pathological FTLD-U
subtypes as well as sporadic amyotrophic
lateral sclerosis (ALS) (Refs 88, 89). The
pathological group, now referred to as FTLD-
TDP (Ref. 22), includes sporadic cases and three
autosomal dominant familial forms of FTLD
(Table 1).
Normal function of TDP-43
TDP-43 is a protein comprising 414 amino acids,
which is encoded by the TARDBP gene on
chromosome 1 (Fig. 3a). It was first cloned as
a human protein capable of binding to the
transactive response DNA of human
immunodeficiency virus Type 1 (Ref. 90), and
later identified as part of a complex involved in
splicing of the cystic fibrosis transmembrane
conductance regulator gene (Ref. 91) and the
apolipoprotein-A-II gene (Ref. 92). TDP-43 is
highly conserved, ubiquitously expressed and
predominantly localised to the nucleus. It
consists of two RNA-recognition motifs and a
glycine-rich C-terminal region (Fig. 3a). Recent
studies have shown that TDP-43 continuously
shuttles between the nucleus and cytoplasm – a
process partially regulated by nuclear
localisation signal (NLS) and nuclear export
signal (NES) motifs (Refs 93, 94). In addition
to its well-characterised role in regulation of
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transcription and splicing, more recent studies
suggest that TDP-43 is involved in other
cellular processes such as micro RNA
biogenesis, apoptosis, cell division, mRNA
stabilisation and regulation of neuronal
plasticity by acting as neuronal activity
response factor (Refs 95, 96). The exon skipping
and splicing inhibitory activity requires the
C-terminal region of TDP-43, which interacts
with other members of the heterogeneous
nuclear ribonucleoprotein (hnRNP) family
(Ref. 97). Finally, TDP-43 can also act as scaffold
for nuclear bodies through interaction with
survival motor neuron protein (Ref. 98).
TDP-43 and pathological spectrum of FTLD-TDP
Expert Reviews in Molecular Medicine © 2009 Cambridge University Press
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Figure 3. TDP-43 and pathological spectrum of FTLD-TDP. (a) Schematic diagram of TDP-43 with its
characteristic functional domains. (b) TDP-43-positive cytoplasmic inclusions in the dentate granule cells.
Note the absence of normal nuclear staining in cells with cytoplasmic inclusions (arrows). (c) Immunoblot
analysis of urea fractions isolated from FTLD-TDP brain shows the highly characteristic biochemical
signature with pathological bands at 25 kDa (*), 45 kDa (**) and a high molecular mass smear (***), in addition
to the normal TDP-43 band. (d) Based on morphological parameters, four FTLD-TDP subtypes can be
delineated, each of which correlates with specific clinical phenotype and genetic abnormalities. Scale bars:
20 mm (b, d). Abbreviations: RRM, RNA recognition motif; NLS, nuclear localisation sequence; NES, nuclear
export sequence.
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TDP-43 is the major pathological
protein in FTLD-TDP
As demonstrated in the initial reports and rapidly
confirmed by numerous subsequent studies,
antibodies against TDP-43 have proven to be
the most sensitive and specific tool to detect all of
the different types of the ub-ir pathology found
in most cases of FTLD-U, including the NCIs,
DNs and neuronal intranuclear inclusions
(NIIs) (Fig. 3b, d) (Refs 88, 89, 99, 100). Moreover,
the pathological forms of TDP-43 demonstrate
evidence of abnormal processing, being
hyperphosphorylated, ubiquitinated and N-
terminally truncated (Ref. 88) (Fig. 3c). Of
potential functional importance, the formation of
TDP-43-positive inclusion bodies (either NCIs or
NIIs) is consistently associated with a dramatic
reduction of the normally diffuse nuclear
staining (Ref. 88) (Fig. 3b), raising the possibility
that essential nuclear functions of TDP-43 might
be lost in FTLD-TDP.
The use of TDP-43 immunohistochemistry has
clarified the spectrum of pathology in this FTLD
subtype, by demonstrating previously
unrecognised ubiquitin-negative pathology,
including glial cytoplasmic inclusions (GCIs)
in cells of presumed oligodendroglial lineage
(Ref. 101), more diffuse neuronal cytoplasmic
‘preinclusions’ (Refs 102, 103) and delicate
neurites in the CA1 region in a subset of FTLD-
TDP (Ref. 104). Antibodies raised against
phosphorylated epitopes of TDP-43 (serine
residues 379, 403, 404, 409 and 410) have
further facilitated the neuropathological
assessment, because they label only abnormal
TDP-43 in inclusions, not the physiological
nuclear TDP-43 (Refs 105, 106, 107).
Pathological subtypes of FTLD-TDP
FTLD-TDP pathology is heterogeneous with
respect to the morphology and laminar
distribution of pathological inclusions, leading
to the description of four distinct pathological
subtypes (Fig. 3d) (Refs 86, 87, 100). Using the
classification scheme originally described by
Sampathu and colleagues, FTLD-TDP Type 1 is
characterised by an abundance of long neuritic
profiles, predominantly in superficial cortical
laminae, with few or no NCIs, NIIs or GCIs.
Type 2 shows a predominance of NCIs in
both superficial and deep cortical layers and
frequent ‘preinclusions’ and GCIs. Neurites
may be present but NIIs are rare or absent.
NCIs, which are typical of MND, are often
present in lower motor neurons. Type 3 cases
have abundant small neuritic profiles and NCIs,
predominantly in the superficial cortical layers.
Moderate numbers of lentiform NIIs can be
found in affected cortical regions, especially
in cases with a positive family history. The
characteristic neuropathological feature of
FTLD-TDP Type 4 pathology is an abundance
of NIIs and DNs with only rare NCIs in cortical
regions, and the absence of inclusions in the
hippocampal dentate granule cells (Refs 108,
109). The relevance of this heterogeneity is
supported by relatively specific correlations
between the various patterns of pathology,
the clinical phenotypes and the known
genetic causes (Table 1, Fig. 3d, see below)
(Refs 86, 99).
Familial FTLD-TDP
FTD due to GRN mutations
Although many of the original FTDP-17 kindreds
were found to haveMAPTmutations (see section
on FTLD-tau), there remained several families
with FTD linked to the same region of
chromosome 17 in which no MAPT mutation
could be identified and some of these were
known to have FTLD-U rather than tau
pathology. This enigma was resolved in 2006,
with the discovery of mutations in GRN, which is
located just 1.7 Mb centromeric to MAPT
(Refs 14, 15). Progranulin (PGRN) is a
multifunctional secreted protein that probably
serves as a neurotrophic growth or survival
factor, with functions in wound healing
and inflammation (Refs 110, 111, 112). To date,
66 different pathogenic mutations have
been described in 199 families (AD&FTD
Mutation database: http://www.molgen.ua.ac.
be/FTDmutations), including all the remaining
original FTDP-17 families. Mutations in GRN are
at least as common a cause of familial FTD as
MAPT (Refs 14, 15, 113, 114). Most pathogenic
mutations are frameshift, splice site or nonsense
mutations that produce premature stop codons,
resulting in mutant mRNA transcripts that
undergo nonsense-mediated decay (Refs 14, 15).
The result of these null mutations is that
the mutant protein is not produced, and
there is a reduction of functional PGRN
(haploinsufficiency). Consistent with this
mechanism is the absence of PGRN in the ub-ir
inclusions (Ref. 15). Instead, the pathology in all
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cases of FTD with GRN mutations is FTLD-TDP
Type 3 with NIIs (Refs 88, 100, 115). A
polymorphic variant in GRN located in the 30-
untranslated region in a binding site for miR-659,
has recently been shown to be a major risk factor
for sporadic FTD, by suppressing the translation
of GRNmRNA (Ref. 116).
Chromosome-9p-linked FTD-MND
Several groups have reported genetic linkage to
chromosome 9p in families with a combination
of FTD and MND (Refs 18, 19, 20). The identity
of the abnormal gene is currently unknown. A
sequence variation in the intraflagellar transport
74 gene (IFT74) was found to segregate with
disease in one family, but no IFT74 mutations
have been detected in other families with
linkage to chromosome 9 (Ref. 117). Although
only a small number of cases have been
reported, the pathology is consistent with
FTLD-TDP Type 2 combined with the
characteristic features of MND (Ref. 100).
FTD due to VCP mutations
Mutations in VCP are the cause of a rare familial
syndrome in which inclusion body myopathy,
Paget disease of the bone and FTD (IMBPFD)
show variable penetrance (Refs 16, 118). To
date, 12 different missense mutations in VCP
have been described in 29 families (AD&FTD
mutation database: http://www.molgen.ua.ac.
be/FTDmutations). The first detailed study of
the neuropathology in cases of IMBPFD with
FTD demonstrated a unique and highly specific
subtype of FTLD-U pathology, characterised by
numerous NIIs and DNs, with very few NCIs
(Refs 109, 119). This was subsequently shown to
be a subtype of FTLD-TDP (Ref. 108) and was
designated as Type 4 (Ref. 21).
VCP is a member of the AAA-ATPase gene
superfamily, and functions as a molecular
chaperone in a plethora of distinct cellular
activities, including ubiquitin-dependent,
endoplasmic-reticulum-associated protein
degradation (ERAD), stress responses,
programmed cell death, membrane fusion,
nuclear envelope reconstruction and post-
mitotic Golgi reassembly. Many of these
activities are directly or indirectly regulated
by the UPS (Refs 118, 120). The mechanisms
whereby VCP mutations cause
neurodegeneration and TDP-43 accumulation
are unclear, although it is tempting to speculate
that alterations of ubiquitin-dependent protein
degradation might have a role.
Molecular mechanisms underlying
FTLD-TDP
The mechanistic aspects of abnormal TDP-43
processing and accumulation, the functional
consequences of these abnormalities (loss-of-
function versus toxic gain-of-function) as well
as the links with GRN and VCP mutations are
currently not well understood. The dramatic
change in subcellular distribution of TDP-43
from the nucleus to the cytoplasm in inclusion-
bearing cells suggests that loss of pivotal
nuclear TDP-43 functions in transcription and
mRNA processing might have a pathogenic
role. Consistent with this hypothesis,
knockdown of TDP-43 in cell lines has been
shown to have important consequences on
essential metabolic processes, such as
regulation of nuclear shape, cell cycle and
apoptosis (Ref. 121). Moreover, TDP-43-
knockout mice are embryonic lethal
(M. Neumann, unpublished). Alternatively, the
generation and sequestration of abnormal TDP-43
species might have a toxic effect. Cortical
inclusions in FTLD-TDP are selectively enriched
for hyperphosphorylated C-terminal fragments
(CTFs), compared with spinal cord inclusions,
which contain more full-length TDP-43
(Refs 107, 122). This suggests that TDP-43 is
differentially processed in different
neuroanatomical regions and that TDP-43 CTFs
might act as seeds for inclusion formation and
aggregation, particularly in cortical neurons.
Recently, one specific cleavage site (Arg208)
was identified in the pathological TDP-43 CTFs
purified from FTLD-TDP brains (Ref. 123).
Overexpression of this CTF in cultured cells
recapitulated some key features of FTLD-TDP,
such as the formation of ubiquitinated and
phosphorylated cytoplasmic aggregates;
however, no clear effect on cell viability was
observed (Ref. 123). An interesting link between
TDP-43 and PGRN was recently reported by
Zhang and co-workers who demonstrated
caspase-dependent cleavage of TDP-43 upon
PGRN knockdown in cultured cells (Ref. 124).
Although it is widely accepted that TDP-43 can
be cleaved by caspases, the influence of PGRN
levels on this process was not replicated by
another group (Ref. 125). Finally, an in vitro
study showed that restricting TDP-43 from
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entering the nucleus by changing the NLS motif
leads to the formation of cytoplasmic TDP-43
aggregates, with subsequent sequestration of
endogenous TDP-43, resulting in a depletion
of nuclear TDP-43 (Ref. 93). Thus, perturbation
of the normal shuttling of TDP-43 between the
nucleus and cytoplasm might predispose to
both the formation of cytoplasmic inclusions
and a loss of nuclear TDP-43.
Although initial studies failed to identify
mutations in the TARDBP gene in FTLD-TDP
(Refs 126, 127, 128), mutations were identified
in familial and sporadic ALS, in early 2008
(Refs 129, 130). At least 30 different TARDBP
mutations have now been identified, mostly in
familial and sporadic ALS (Refs 131, 132, 133,
134, 135, 136, 137, 138, 139, 140). However, very
recently, a TARDBP mutation (G295S) was
reported in two unrelated patients with FTD
and MND (Ref. 141). Except for the Y374X
truncation mutation, all others are missense
mutations, mostly in exon 6, which effect highly
conserved amino residues in the C-terminal
region of TDP-43. Elucidating the functional
consequences of ALS-causing TARDBP
mutations is likely to also provide important
insights into the mechanism of
neurodegeneration in FTLD-TDP. One current
hypothesis is that TARDBP mutations might
interfere with protein–protein interaction,
thereby affecting intracellular transport or
crucial transcriptional and splicing activities.
Alternatively, the mutations might increase the
generation of CTFs, promote the aggregation of
TDP-43 and/or result in abnormal
phosphorylation (Refs 129, 131, 135).
FTLD-UPS
Although initial data suggested that all FTLD-U
cases are characterised by TDP-43 pathology,
recent follow-up studies have demonstrated
that there are some cases in which the
pathological inclusions are only detectable
with markers of the ubiquitin proteasome
system (FTLD-UPS), in which the pathological
ubiquitinated protein(s) is still unknown
(Refs 100, 104, 142, 143). The most common
subtype of FTLD-UPS, representing 10–20% of
all FTLD-U cases, was recently described in
detail (Refs 144, 145). The highly unusual and
consistent clinical and pathological features of
these cases suggest that they represent a newly
recognised, discrete entity and the term atypical
FTLD-U (aFTLD-U) was introduced. The
clinical phenotype is sporadic, early-onset FTD
with severe progressive behavioural and
personality changes in the absence of aphasia or
significant motor features. In addition to
frontotemporal atrophy, severe degeneration of
the anterior striatum and hippocampal sclerosis
are common findings in aFTLD-U. TDP-43-
negative, ubiquitin-positive and p62-positive
NCIs are most abundant in the frontal and
temporal neocortex and hippocampus (Fig. 4a).
However, the most intriguing pathological
feature is the presence of NIIs in the dentate
granule cells and cortical pyramidal neurons
with a unique morphology, where they appear as
elongated straight or curved bars or thick twisted
filaments (Fig. 4b, c). The immunohistochemical
profile of these NIIs is also unusual and different
from the NCIs, because they are reactive for
ubiquitin but not for p62 (Fig. 4d).
Familial FTD linked to chromosome 3 (FTD-3),
due to mutations in CHMP2B (Ref. 17) has also
recently been shown to have FTLD-UPS
pathology (Ref. 146). So far, four families have
been identified with different CHMP2B
mutations (AD&FTD Mutation database: http://
www.molgen.ua.ac.be/FTDmutations). CHMP2B
belongs to the chromatin-modifying protein/
charged multivesicular body protein family and
is a component of ESCRT-III (endosomal sorting
complex required for transport III), a complex
involved in the degradation of surface receptor
proteins and the formation of endocytotic
multivesicular bodies. Although previous
reports failed to detect abnormal protein
deposits in brains of patients with FTD-3, a
recent study demonstrated the presence of
granular NCIs that were immunoreactive for
ubiquitin and p62, but negative for TDP-43 and
tau, predominantly in the dentate granule cells
of the hippocampus (Fig. 4e) (Ref. 146).
FTLD-IF
Neuronal intermediate filament inclusion disease
(NIFID) is an uncommon neurological disorder
(Ref. 147) with pathology characterised by
neuronal inclusions that are immunoreactive
for all of the Class IV intermediate filaments
(IFs) [light, medium and heavy neurofilament
(NF) subunits and a-internexin] (Refs 148, 149).
The typical clinical presentation is early-onset
sporadic FTD, associated with a pyramidal
and/or extrapyramidal movement disorder
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(Refs 148, 150, 151, 152, 153, 154, 155, 156, 157).
Additional clinical manifestations that have
been reported include falls, dystonia,
myoclonus, ophthalmoplegia, memory deficits,
seizures, eating disorders and psychiatric
symptoms. There have been two cases
published with possible childhood onset
(Refs 151, 153) and two with a questionable
family history (Refs 152, 153).
The neuropathological findings in NIFID are
heterogeneous, but have a number of consistent
features (Refs 148, 150, 151, 152, 153, 154, 155,
156, 157). Chronic degenerative changes may
affect a variety of cortical and subcortical
regions, with the frontal and temporal lobes
and caudate nucleus most consistently and
severely involved. Several types of neuronal
inclusions are found. The most common are
small round Pick-body-like inclusions that are
well-defined, slightly eosinophilic or basophilic
and rarely argyrophilic (Fig. 5a). These are
variably immunoreactive for ubiquitin, NF and
a-internexin but negative for tau, a-synuclein
and TDP-43 (Fig. 5b) (Ref. 149). The
ultrastructure is a combination of electron-
dense granular material and dispersed short
filaments (Refs 156, 158, 159). These are
numerous in affected regions of cerebral
neocortex, hippocampus and in select
subcortical regions. Hyaline conglomerate
inclusions are less frequent, and appear as
irregular, multilobulated masses that often
compress the nucleus (Fig. 5c). They are weakly
eosinophilic, with a glassy, filamentous
appearance and sometimes have a dense,
brightly eosinophilic core. These stain intensely
with the Bielschowsky silver method and
are more consistently and intensely
immunoreactive for IFs (Fig. 5d). The
ultrastructure is compact, interlacing bundles of
filaments (Ref. 158). NCI with other
morphologies may also be present, and there
are often IF-immunoreactive swollen axons. A
less consistent feature is the presence of
eosinophilic NIIs that are intensely
immunoreactive for ubiquitin but generally not
reactive for IFs (Fig. 5e) (Refs 149, 153, 154, 158).
Neuronal IFs include the triplet of light (68
kDa), medium (145 kDa) and heavy (200 kDa)
NF subunits, a-internexin and peripherin
(Ref. 160). Based on sequence homology, the NF
proteins and a-internexin have been grouped
together as Class IV IFs (Ref. 161). The
expression of a-internexin precedes that of NFs
during development and, in the adult brain,
a-internexin is expressed at lower levels and in
more restricted neuronal populations (Ref. 162).
The Class IV IFs can coassemble (Ref. 163), and
Pathological spectrum of FTLD-UPS
Expert Reviews in Molecular Medicine 
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Figure 4. Pathological spectrum of FTLD-UPS.
An aFTLD-U case with ubiquitin-immunoreactive
cytoplasmic (a) and intranuclear inclusions (b, c) in
dentate granule cells. (d) The cytoplasmic
inclusions are also immunoreactive for p62 but
the intranuclear inclusions are not. (e)
Familial FTD caused by CHMP2B mutations
(FTD-3) also have ubiquitin-positive cytoplasmic
inclusions in the dentate granule cells. a–c, e,
ubiquitin immunohistochemistry; d, p62
immunohistochemistry. Scale bar: 20 mm (a, d, e);
10 mm (b, c).
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are part of the normal neuronal cytoskeleton, that
is involved in maintaining cell structure and
intracellular transport (Ref. 164). The degree
and pattern of phosphorylation of NFs is
essential for normal intracellular localisation
and function (Ref. 160). The inclusions in NIFID
are variably reactive with antibodies against
phosphorylated and phosphorylation-independent
epitopes of all three NF subunits; however, a-
internexin immunohistochemistry is the most
sensitive (Refs 148, 149). Although NF can be a
minor component of the characteristic inclusion
bodies of many different neurodegenerative
conditions (including AD, PD, DLB and MND)
(Ref. 160), a-internexin immunoreactivity is
relatively specific for NIFID (Ref. 165). Because the
abnormal protein aggregates found in NIFID are
immunoreactive for IFs but not for any other
proteins currently known to be associated with
neurodegenerative disease, the designation of
NIFID or FTLD-IF is appropriate. However, the fact
that IF proteins show no abnormal molecular
modification in NIFID (Refs 149, 158, 165) and no
pathogenic variants of the corresponding genes
have been identified (Ref. 166), leaves open the
possibility that some other protein might have a
more central role in the pathogenesis of this
condition (Refs 150, 153).
BIBD
BIBDisatermthathasbeenusedforasmallnumber
of clinically and pathologically heterogeneous
cases, in which the common finding is neuronal
cytoplasmic inclusions that are basophilic
with haematoxylin and eosin stain (Fig. 5f). The
clinical phenotypes include sporadic ALS
(Ref. 167), familial ALS (Ref. 168), ALS with
dementia (Refs 150, 169, 170) and pure FTD
(Refs 150, 171). Although cases of BIBD with
clinical FTD show chronic degeneration of the
frontotemporal neocortex, the inclusions tend to
be most numerous in subcortical regions, such as
the basal ganglia and brainstem tegmentum
(Refs 150, 171). The inclusions are round, oval or
crescentic, weakly argyrophilic and can be
detected with histochemical stains for RNA (such
as cresyl violet, methyl green pyronine and
acridine orange). Immunohistochemical studies
have found them to be negative for tau, a-
synuclein, NF, a-internexin, tubulin, actin and
TDP-43 (Refs 100, 150, 169, 171). Reports of
ubiquitin immunoreactivity are inconsistent but
some are positive for p62 (Ref. 150). The
biochemical composition of the signature
inclusions in BIBD is not presently known.
FTLD-ni
Until recently, most cases of tau-negative FTLD
were thought to have no cellular inclusions and
were classified as DLDH (Ref. 78). However,
with the use of sensitive immunohistochemical
techniques, most of these cases are found to
have ubiquitin-immunoreactive pathology
(previously designated FTLD-U) (Ref. 85) that
is usually also reactive for TDP-43 (Ref. 99).
Neuropathology of rare FTLD 
subtypes
Expert Reviews in Molecular Medicine 
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Figure 5. Neuropathology of rare FTLD subtypes.
(a–d) Neuronal intermediate filament inclusion
disease. The most common type of inclusion is
Pick-body-like inclusions that are visible with
haematoxylin and eosin stain (a) and
immunoreactive for a-internexin (b). Hyaline
conglomerate inclusions are also present (c) and
are immunoreactive for phosphorylated
neurofilament (d). (e) Neuronal intranuclear
inclusions that are present in some cases of FTLD-
IF are strongly immunoreactive for ubiquitin but do
not stain for intermediate filaments. Note the
presence of a Pick-body-like inclusion in the
cytoplasm of the same neuron. (f) Typical inclusion
of basophilic inclusion body disease. Scale bar:
20 mm (a, c–f); 40 mm (b).
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Cases of true DLDH are now considered to
be uncommon, and the existence of DLDH as
a distinct entity has been questioned. The
terminology that is now recommended for rare
cases of FTLD in which no inclusions can be
demonstrated with special histochemical stains
or immunohistochemistry is FTLD-ni (no
inclusions) (Ref. 22).
Other pathological causes of FTD
There are a number of rare neurodegenerative
conditions, with unknown biochemical defects,
that can present as FTD, such as hereditary
diffuse leukoencephalopathy with spheroids
(Ref. 172) and neuronal intranuclear inclusion
disease (Ref. 173). In addition, most of the
common neurodegenerative causes of dementia
can occasionally fulfill clinical diagnostic
criteria for FTD. Although the frequency of
these ‘frontal variants’ and their overall
contribution to FTD is difficult to determine,
some studies have found more than 20% of
clinical FTD to be associated with the pathology
of AD, DLB, CJD or vascular disease (Refs 174,
175). The frontal variant of AD is best
recognised and could account for 17% of all
FTD (Refs 174, 175). Attempts to demonstrate
a correlation between the regional severity of
the AD pathology and the clinical phenotype
have been inconsistent (Refs 56, 57, 176). One
recent study has described additional glial tau
pathology in cases of AD with clinical PPA,
suggesting a pathological overlap with FTLD-
tau (Ref. 177). Another recent finding of interest
is the presence of TDP-43 pathology in a
significant proportion of AD and DLB cases
(Refs 178, 179, 180, 181, 182). Although this
often has a restricted anatomical distribution,
it is sometimes extensive and might closely
resemble FTLD-TDP (Ref. 181). Whether or not
this additional pathology alters the clinical
phenotype is yet to be determined.
Outstanding research questions
Despite the enormous gains made over the past
few years in our understanding of the molecular
basis of FTD, many fundamental issues are still
unresolved. The FTLD gene on chromosome 9
remains to be identified and there is probably at
least one other genetic cause of familial FTLD-
tau. The normal functions of PGRN and TDP-43
in the nervous system need to be clarified, as do
the mechanisms by which mutations in GRN,
VCP and TARDBP lead to TDP-43 pathology.
The possible role of GRN and TARDBP genetic
variants in other (non-FTLD) neurodegenerative
disease requires further investigation. The
development of new animal models, particularly
of FTLD-TDP, should help to answer these
questions and will be crucial in the development
of targeted therapies. Efforts to develop in vivo
biomarkers that distinguish different subgroups
of FTLD and aid in diagnosis and monitoring
of disease are still preliminary (Refs 183, 184,
185, 186). Despite the enormous amount of work
that lies ahead, recent discoveries have greatly
improved our ability to offer meaningful genetic
counselling for FTLD families and bring us
much closer to developing useful diagnostic
tests and rational therapies.
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Further reading, resources and contacts
Publications
Ballatore, C., Lee, V.M. and Trojanowski, J.Q. (2007) Tau-mediated neurodegeneration in Alzheimer’s disease
and related disorders. Nature Reviews Neuroscience 8, 663-672
A review of role of tau protein in neurodegeneration.
Buratti, E. and Baralle, F.E. (2008) Multiple roles of TDP-43 in gene expression, splicing regulation, and human
disease. Frontiers in Bioscience 13, 867-878
This is an excellent review on the biology of TDP-43.
Ahmed, Z. et al. (2007) Progranulin in frontotemporal lobar degeneration and neuroinflammation. Journal of
Neuroinflammation 4, 7
A review of progranulin function and role in FTD.
Websites
The website of the Association for Frontotemporal Dementias (AFTD), a US nationwide non-profit organisation
whosemission is to promote and fund research into finding the cause and cure for FTD, provides information,
education, and support to persons diagnosed with FTD and their families and caregivers; and educates
physicians and allied health professionals about FTD:
http://www.ftd-picks.org/
The website from University of California, San Francisco provides information on clinical and research aspects
of FTD and gives information on clinical trials:
http://memory.ucsf.edu/ftd/
The AD&FTDMutation database provides a current list of known FTLD gene mutations, including the number of
affected families:
http://www.molgen.ua.ac.be/FTDmutations
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Figure 1. Tau isoforms and tau gene mutations.
Figure 2. Pathological features in FTLD-tau.
Figure 3. TDP-43 and pathological spectrum of FTLD-TDP.
Figure 4. Pathological spectrum of FTLD-UPS.
Figure 5. Neuropathology of rare FTLD subtypes.
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Table 1. Recommended nomenclature for frontotemporal lobar degenerations.
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